Health ministry approves Tresiba as only basal insulin for treatment of Type-1 diabetes

Novo Nordisk announced the approval by the Ministry of Health of Insulin Degludec (Tresiba) as the only basal insulin for the treatment of Type-1 diabetes, from the age of one year. This announcement came as a medical and scientific breakthrough for the leading global diabetes healthcare company. The approval was announced during a press conference and attended by Mona Salem, professor of paediatrics, diabetes and endocrinology at Ain Shams University; Samir Helmy Assaad, professor of internal medicine and diabetes, Faculty of Medicine,Alexandria University;and DaliaToaima, Clinical, Medical, Regulatory, and Quality Director at Novo Nordisk Egypt.The administration of Degludec (Tresiba) in one-yearold infants with type-1 diabetes received regulatory approvals from renowned scientific authorities such as the EMA, the FDA, as well as the Egyptian Ministry of Health.

“Tresiba is a long acting insulin, prescribed for patients with Type-1 and Type-2 diabetes as a once a day dosing, and it has been available in the local market for a while.Today, we are proud to announce the approval of the Ministry of Health for Insulin Degludec (Tresiba) as the only basal Insulin for the treatment ofType-1 diabetes from the age of one year.This is considered as another scientific breakthrough for the leading global diabetes healthcare company,” said Toaima.